Related Experiment Video
Updated: Jul 8, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2
Silvia Pomella1,2, Matteo Cassandri1,3, Lucrezia D'Archivio1
1Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Roma, Italy.
Abstract:
Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor MYOD that, whilst essential for survival, cannot support differentiation. Here we discover SKP2, an oncogenic E3-ubiquitin ligase, as a critical pro-tumorigenic driver in FN-RMS. We show that SKP2 is overexpressed in RMS through the binding of MYOD to an intronic enhancer. SKP2 in FN-RMS promotes cell cycle progression and prevents differentiation by directly targeting p27Kip1 and p57Kip2, respectively. SKP2 depletion unlocks a partly MYOD-dependent myogenic transcriptional program and strongly affects stemness and tumorigenic features and prevents in vivo tumor growth. These effects are mirrored by the investigational NEDDylation inhibitor MLN4924. Results demonstrate a crucial crosstalk between transcriptional and post-translational mechanisms through the MYOD-SKP2 axis that contributes to tumorigenesis in FN-RMS. Finally, NEDDylation inhibition is identified as a potential therapeutic vulnerability in FN-RMS.
Insights
We identified SKP2 as a key driver in fusion-negative rhabdomyosarcomas (FN-RMS). Targeting SKP2 or NEDDylation shows promise for treating this pediatric cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Rhabdomyosarcomas (RMS) are pediatric cancers with distinct subtypes, including Fusion-Negative (FN)-RMS.
- While MYOD is crucial for RMS survival, it doesn't induce differentiation.
- FN-RMS often harbors RAS pathway mutations.
Purpose of the Study:
- To identify novel pro-tumorigenic drivers in FN-RMS.
- To elucidate the role of SKP2 in FN-RMS pathogenesis.
- To explore therapeutic vulnerabilities in FN-RMS.
Main Methods:
- Investigated SKP2 expression and regulation by MYOD in RMS.
- Assessed the impact of SKP2 depletion on cell cycle, differentiation, and stemness.
- Utilized the NEDDylation inhibitor MLN4924 to study its effects in FN-RMS models.
- Evaluated in vivo tumor growth after SKP2 manipulation.
Main Results:
- Discovered SKP2 overexpression in RMS, driven by MYOD binding to an intronic enhancer.
- Demonstrated that SKP2 promotes cell cycle progression and inhibits differentiation by targeting p27Kip1 and p57Kip2.
- SKP2 depletion reactivated myogenic programs, reduced stemness, and inhibited tumor growth.
- MLN4924 mimicked the effects of SKP2 inhibition.
Conclusions:
- Established a critical MYOD-SKP2 axis linking transcriptional and post-translational regulation in FN-RMS tumorigenesis.
- Identified SKP2 as a crucial oncogenic driver in FN-RMS.
- Highlighted NEDDylation inhibition as a potential therapeutic strategy for FN-RMS.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Destabilization of Microtubules
Satellite Stem Cells and Muscular Dystrophy